PARIS – The contrast is especially sharp in the way clinicians speak about renal denervation and the way companies promote this new procedure. In the language of physicians, the idea that a device-based therapy can reduce or replace drug-based treatment for persistent hypertension is only a "notion," an argument or perhaps a hypothesis. To listen to company representatives, it's a done deal.